Arbutus Biopharma Corporation
ABUS
$4.45
$0.020.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.49% | 522.19% | 15.14% | -26.62% | -71.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.49% | 522.19% | 15.14% | -26.62% | -71.25% |
| Cost of Revenue | -59.52% | -64.65% | -41.84% | -49.84% | -29.23% |
| Gross Profit | 59.42% | 137.91% | 48.13% | 53.07% | 16.61% |
| SG&A Expenses | -32.91% | -55.90% | 9.79% | -7.63% | -22.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.10% | -61.79% | -28.60% | -40.34% | -27.68% |
| Operating Income | 52.53% | 108.95% | 32.09% | 41.77% | 18.18% |
| Income Before Tax | 60.73% | 112.74% | -37.21% | 35.11% | 1.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.73% | 112.74% | -37.21% | 35.11% | 1.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.73% | 112.74% | -37.21% | 35.11% | 1.92% |
| EBIT | 52.53% | 108.95% | 32.09% | 41.77% | 18.18% |
| EBITDA | 51.67% | 109.15% | 32.56% | 42.39% | 18.34% |
| EPS Basic | 61.27% | 112.54% | -26.33% | 42.32% | 13.08% |
| Normalized Basic EPS | 53.93% | 114.75% | 38.41% | 50.99% | 29.78% |
| EPS Diluted | 61.27% | 109.09% | -26.33% | 40.05% | 13.08% |
| Normalized Diluted EPS | 53.93% | 114.75% | 38.41% | 50.99% | 29.78% |
| Average Basic Shares Outstanding | 1.47% | 1.87% | 8.59% | 12.52% | 12.83% |
| Average Diluted Shares Outstanding | 1.47% | 2.32% | 8.59% | 12.52% | 12.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |